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I.  INTRODUCTION 
Pharmaceutical drugs are an extremely important part of 
medical care and integral to maintaining a person’s health and 
wellbeing. Given that most American citizens will have to purchase a 
pharmaceutical during their lifetime, affordability is an important 
issue that affects everyone. Pharmaceuticals are supposed to help 
afflicted Americans, not harm them financially. A dilemma exists 
when pharmaceuticals are prescribed as necessary to a person’s 
medical care and treatment, but the person cannot afford to purchase 
them. Pharmaceuticals in the United States should not be cost 
prohibitive. How can we balance the interests of people who need 
pharmaceuticals with the interests of pharmaceutical companies? The 
answer is negotiation. However, this seemingly simple answer does 
not come without complications. Medicare, the largest buyer of 
brand-name prescription drugs in the United States, is not allowed to 
negotiate with pharmaceutical companies. Therefore, this comment 
will focus on Medicare’s inability to negotiate with pharmaceutical 
companies. 
This comment addresses the high price of brand-name 
pharmaceuticals in the United States and suggests how the price of 
pharmaceuticals can be lowered. This comment will compare the 
United States’ system, that lacks price controls, to the systems 
implemented in Canada and the United Kingdom. Both Canada and 
the United Kingdom allow their governments to negotiate directly 
with pharmaceutical companies. As a result, the price of brand-name 
pharmaceuticals in Canada and the United Kingdom are drastically 
lower than the price of brand-name pharmaceuticals in the United 
States. In addition to negotiation, Canada and the United Kingdom 
both regulate pharmaceutical prices. Canada regulates the maximum 
price of the pharmaceuticals and the United Kingdom regulates the 
amount of profit pharmaceuticals generate. This comment will argue 
that the United States government should allow Medicare to 
negotiate directly with brand-name pharmaceutical companies, 
referencing both Canada and the United Kingdom as models for 
regulating the prices of brand-name pharmaceuticals. 
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This comment proceeds in seven parts. Part I of this 
comment discusses the pricing of brand-name pharmaceuticals in the 
United States. This discussion will include the history of Medicare, 
the prohibition of Medicare directly negotiating with brand-name 
pharmaceutical companies, Medicare’s purchasing process, and a 
recent example of a brand-name pharmaceutical company increasing 
the price of their pharmaceutical. Part II of this comment discusses 
the impact high priced brand-name pharmaceuticals have on 
consumers. Part III of this comment explains Canada’s approach to 
setting prices for brand-name pharmaceuticals and Part IV explains 
the approach taken by the United Kingdom when setting prices of 
brand-name pharmaceuticals. Part V of this comment analyzes and 
explains how allowing Medicare to negotiate directly with brand-
name pharmaceutical companies would decrease the price of brand-
name pharmaceuticals. This part of the comment also discusses what 
processes the United States should implement and addresses 
arguments against allowing Medicare to negotiate directly with brand-
name pharmaceutical companies. Part VI of this comment lists other 
possible ways to lower pharmaceutical prices in the United States, but 
explains why allowing Medicare to negotiate directly with brand-
name pharmaceutical companies would best achieve that goal. Part 
VII summarizes and concludes the comment. 
II.  PHARMACEUTICAL SALES AND PRICING IN THE UNITED STATES 
The price of brand-name pharmaceuticals in the United 
States is higher than any other developed country in the world.1 In 
order to grasp the severity of this problem, one must look to some 
statistics. The International Federation of Health Plans found that 
people in the United States pay two to six times more than the rest of 
the world for brand-name pharmaceuticals.2 A Reuters analysis 
showed that the United States pays as much as seven times more 
                                                 
 1 Nadia Kounang, Why pharmaceuticals are cheaper abroad, CNN (Sept. 28, 
2015, 8:46AM), www.cnn.com/2015/09/28/health/us-pays-more-for-drugs. 
 2 Id. (comparing the price of brand-name pharmaceuticals in the United 
States to the price of brand-name pharmaceuticals in other countries). 
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than the United Kingdom for some top-selling drugs.3 Prices for top 
pharmaceuticals increased by 127 percent from 2008 to 2014.4 
Pharmaceuticals are far outpacing inflation.5 Moreover, drug prices 
have risen approximately 10 percent over a one-year period ending in 
May 2016.6 The inflation rate at that time was only 1 percent.7 One 
reason for the high prices is that Medicare cannot directly negotiate 
prices with brand-name pharmaceutical companies. Medicare has 
tremendous bargaining power to negotiate lower prices being that it 
is the largest buyer of pharmaceuticals in the United States. Because 
Medicare cannot negotiate, however, pharmaceutical companies place 
outrageous price tags on their products. The Director of Memorial 
Sloan Kettering’s Center for Health Policy and Outcomes said 
pharmaceutical companies place high prices on pharmaceuticals 
simply “because they can.”8 
A.  History of Medicare and Its Inability to Negotiate in the United 
States 
In 1965 the Social Security Act established a health insurance 
program called Medicare.9 Medicare consists of four parts, Parts A, B, 
C, and D.10 Medicare Part D was created by the Medicare 
                                                 
 3 Carolyn Y. Johnson, Why America pays so much more for drugs, THE 
WASHINGTON POST (Feb. 25, 2016), https://www.washingtonpost.com/news 
/wonk/wp/2016/02/25/why-america-pays-so-much-more-for-drugs/. 
 4 Ben Hirschler, Americans Pay More For Drugs Than Anyone In The World, 
THE HUFFINGTON POST (Oct. 12, 2015, 12:21 PM), https://www.huffingtonpost 
.com/entry/americans-pay-more-for-drugs-than-anyone-in-the-world_us_561bd 
a8fe4b0e66ad4c89449. 
 5 See Johnson, supra note 3. 
 6 Brad Tuttle, Prescription Drug Prices in America Are Rising Like No Other 
Industry, TIME (July 14, 2016), http://time.com/money/4406167/prescription-
drug-prices-increase-why/. 
 7 Id. 
 8 See Kounang, supra note 1 (explaining that brand-name pharmaceutical 
companies place excessive prices on their products because “[w]e have no rational 
system in the U.S. for managing prices of drugs”). 
 9 Social Security Amendments of 1965, Pub. L. No. 89-97, 79 Stat. 286 
(1935) (amended 1965). 
 10 Part A covers medically necessary hospital, skilled nursing facility, home 
health, and hospice care; Part B covers medically necessary doctor’s services such 
as preventive care, outpatient services, x-rays, and laboratory tests; Part C is not a 
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Prescription Drug, Improvement, and Modernization Act.11 It 
amended Title XVIII of the Social Security Act to provide a 
voluntary prescription drug benefit under Medicare.12 This federal law 
was signed by President George W. Bush on December 8, 2003.13 
The Medicare Prescription Drug, Improvement, and Modernization 
Act prohibits Medicare from negotiating directly with pharmaceutical 
companies.14 
B.  The Procedure Medicare Utilizes to Purchase Pharmaceuticals 
Due to the Prohibition on Negotiating Directly with 
Pharmaceutical Companies 
The United States bars Medicare from negotiating for lower 
prices with pharmaceutical companies.15 Part B and Part D of 
Medicare deal with the prescription drug market.16 Part B determines 
the price of drugs by the average sales price in the previous quarter.17 
Prices under Part D are fixed through private prescription drug plans 
negotiating with pharmaceutical companies.18 The prescription drug 
plans then submit their bids to the Center for Medicare and Medicaid 
Services (CMS), which determines the purchase price of the drug and 
                                                 
separate benefit, but rather it allows private health insurance companies to give 
Medicare benefits; Part D provides outpatient prescription drug coverage and is 
only provided through private insurance companies that have government 
contracts. See What does Medicare cover (Parts A, B, C, and D)?, MEDICARE 
INTERACTIVE, https://www.medicareinteractive.org/get-answers/introduction-to-
medicare/explaining-medicare/what-does-medicare-cover-parts-a-b-c-and-d (last 
visited Nov. 13, 2017). 
 11 Medicare Prescription Drug, Improvement, and Modernization Act of 
2003, Pub. L. No. 108-173, 117 Stat. 2066 (2003). 
 12 Id. 
 13 Id. 
 14 Id. 
 15 Id. 
 16 What does Medicare cover (Parts A, B, C, and D)?, supra note 10. 
 17 John B. Kirkwood, Article, Buyer Power and Healthcare Prices, 91 WASH. L. 
REV. 253, 262 (2016) (explaining that “Medicare is a price taker” due to a lack of 
negotiating with pharmaceutical companies by stating “[i]n essence, what drug 
companies charged the prior quarter determines what they can charge this 
quarter”). 
 18 Id. (explaining how the price Medicare pays for brand-name 
pharmaceuticals is set). 
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the price beneficiaries must pay.19 A Medicare beneficiary then joins 
and pays premiums to a prescription drug plan to obtain prescription 
drugs.20 Pharmaceutical companies also negotiate privately with 
insurance companies and employers. Although the private 
prescription drug plans can discount the price of the prescription 
drugs, the discounts would be greater if the largest buyer, Medicare, 
could negotiate with drug manufacturers.21 If Medicare was allowed 
to negotiate directly with pharmaceutical companies, the prices would 
decrease as a result of leverage gained from the threat of lost 
business. 
C.  Recent Example of a High Priced Brand-name Pharmaceutical in 
the United States 
1. The EpiPen Price Increase 
Recently, United States citizens have been outraged by the 
increase in the price of EpiPen. The drug in EpiPen is epinephrine.22 
EpiPens are injected into people who experience anaphylaxis, an 
allergic reaction that causes airways to close.23 Over sixty million 
Epipens have been dispensed from 1987 to May 2016, indicating that 
there is a large demand for this drug in the United States.24 Mylan 
Pharmaceuticals, the manufacturer of EpiPen, has increased the price 
                                                 
 19 Joshua C. Snow, Note, Reducing Pharmaceutical Fraud: In Search of The 
Cocktail Prescription, 41 PUB. CONT. L.J. 1027, 1030 (2012). 
 20 Id. at 1031 (citing Susan Adler Channick, The Medicare Prescription Drug 
Improvement and Modernization Act of 2003: Will It Be Good Medicine for U.S. Health 
Policy?, 14 ELDER L.J. 237, 246-48 (2006)). 
 21 See Kirkwood, supra note 17, at 269. 
 22 EpiPen is used to treat anaphylaxis which is a potentially life threatening 
allergic reaction that can occur within a couple of minutes. Anaphylaxis can be 
caused by allergens such as foods, insect bites, and medications. Anaphylaxis causes 
skin irritation, swelling of the lips, tongue, and airways. See Frequently Asked 
Questions, EPIPEN, https://www.epipen.com/about-epipen/faq (last visited Nov. 
13, 2017). 
 23 Jana Kasperkevic, New York investigates EpiPen maker Mylan after price hike 
of medication, THE GUARDIAN (Sept. 2, 2016), https://www.theguardian.com/ 
business/2016/sep/06/epipen-price-hike-mylan-new-york-investigation. 
 24 Frequently Asked Questions, supra note 22, (“EpiPen Auto-Injector has 
been available for more than 25 years.”). 
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of this allergy medication by 471 percent since 2007.25 The cost of 
Epipen recently rose from $100 to more than $600.26 Citizens are 
worried about this drastic price increase because families often have 
to purchase multiple EpiPens to keep in different locations such as at 
school and home.27 Additionally, like other drugs EpiPens have an 
expiration date and must be refilled before they expire.28 Therefore, if 
the EpiPen is not used before it expires, the money paid for it is 
essentially lost. 
2. Americans Turn to Canada 
A number of Americans have turned to Canada for lower 
priced EpiPens.29 According to the general manager of the Canadian 
International Pharmaceutical Association, the price of a single 
EpiPen in Canada ranges from $100 to $145.30 This difference in 
price is substantial. The price of EpiPen in Canada is approximately 
$500 cheaper than the price of EpiPen in the United States. 
Therefore, a number of Americans have purchased EpiPen from 
Canadian online pharmacies to avoid high prices in the United 
States.31 
3. Mylan Pharmaceuticals’ Solution to the Price Increase 
 Mylan Pharmaceuticals, the manufacturer of EpiPen, 
responded to the outrage by saying they would offer discounts to 
customers.32 Mylan Pharmaceuticals’ short-term solution to satisfy 
customers is to offer coupons for up to $300 to patients who face 
                                                 
 25 In 2007 Mylan acquired EpiPen. Id. 
 26 Gillian Mohney, EpiPen Price Hike Prompts Some US Families to Buy the 
Drug in Canada, ABC NEWS (Aug. 31, 2016, 12:30 PM), http://abcnews.go.com 
/Health/epipen-price-hike-prompts-us-families-buy-drug/story?id=41769704. 
 27 Id. (stating that one woman used to keep three or even four EpiPen 
packs in different areas when her son was a child). 
 28 Frequently Asked Questions, supra note 22. 
 29 See Mohney, supra note 26. 
 30 Id. 
 31 Id. 
 32 Nathan Bomey, EpiPen Maker to offer discounts after price hike firestorm, USA 
TODAY (Aug. 26, 2016, 7:43 AM), http://www.usatoday.com/story/money 
/2016/08/25/epipen-maker-offer-discounts-after-firestorm/89329122/. 
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high out-of-pocket costs.33 Additionally, Mylan Pharmaceuticals 
stated that they planned to make a generic version of EpiPen so 
people would not have to pay for the expensive brand-name 
EpiPen.34 However, there is currently no generic or brand name drug 
that is similar to EpiPen.35 
The Chairman of the House Oversight and Government 
Reform Committee wrote a letter to the CEO of Mylan 
Pharmaceuticals. He stated that Mylan has a monopoly over the 
EpiPen market and their command of the market has given Mylan 
the ability to charge any price they want for EpiPen.36 The 
unfortunate result is that consumers must pay the high prices for 
pharmaceuticals or go without their medication. 
                                                 
 33 Id. (“Mylan also said it would double the income level at which families 
are eligible for assistance in purchasing the medication to 400% of the federal 
poverty level, which stands at $24,300 for a family of four.”). 
 34 The price of the generic EpiPen will cost approximately $300 for a two 
pack. A mother who purchases EpiPen for her child was interviewed by ABC 
News and said the generic price could still be prohibitive to many families. See 
Mohney, supra note 26. 
 35 There is no generic substitute to EpiPen which means that people in 
need of that medication have no other option for proper treatment. They must 
purchase the brand-name EpiPen in order to receive the treatment they need. See 
Bomey, supra note 32. 
 36 Letter from Jason Chaffetz, House Oversight and Government Reform 
Committee Chairman to Heather Bresch, Chief Executive Officer of Mylan, Inc. 
(Aug. 29, 2016), http://democrats.oversight.house.gov/sites/democrats.oversight 
.house.gov/files/documents/2016-08-29%20JC%20and%20EEC%20%20to%20 
Bresch- Mylan%20EpiPen%20Pricing.pdf, (“Mylan has a virtual monopoly over 
the epinephrine auto-injector market. A national dependence on accessibility to 
EpiPens has been well established since Mylan’s acquisition of the device in 2007. 
This command of the market has given Mylan the unbridled ability to increase the 
price of the two-pack EpiPen.”); see also Brad Tuttle, Prescription Drug Prices in 
America Are Rising Like No Other Industry, TIME (July 14, 2016), http://time.com 
/money/4406167/prescription-drug-prices-increase-why/(stating medication is 
essential so people have little choice but to buy them no matter how much they 
cost). 
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III.  THE CONSEQUENCES OF HIGH PHARMACEUTICAL PRICES 
The EpiPen example is largely demonstrative of the current 
pharmaceutical market in the United States. The price of 
pharmaceuticals in the United States is often a large barrier for 
people in need of treatment. Consumers of pharmaceuticals in the 
United States often have to decide whether to fill their prescriptions 
or buy other daily necessities such as food. Some individuals have to 
decide whether to go bankrupt and obtain their medication or forego 
their medicine altogether.37 Pharmaceuticals can be cost prohibitive. 
It is a regular occurrence for people to not fill their prescriptions 
once they find out the price, and thus sacrifice the treatment they 
need. Experts estimate that approximately 20 percent of prescribed 
medications are never filled.38 While there are other reasons that 
patients do not take or fill their prescriptions, such as side effects and 
lack of symptoms, the biggest reason is the cost of prescriptions.39 
Pharmaceuticals are essential to a patient’s health and in extreme 
situations a patient could die from not taking their prescriptions.40 
Therefore, the people of the United States must pay a high price for 
                                                 
 37 Brendan Murphy, Note, Getting High on Profits: An Analysis of Current State 
and Federal Proposals to Rein in Soaring Drug Prices, 12 J. HEALTH & BIOMED. L. 37, 64-
5 (2016) (citing Lee Graczyk, Americans can’t afford U.S. medication, need a safe alternative 
(Nov. 12, 2014), http://thehill.com/blogs/congress-blog/healthcare/223650-
americans-cant-afford-us-medication-need-a-safe-alternative). 
 38 Christina Sumners, Why People Aren’t Taking Their Prescription Medications, 
VITAL RECORD (Mar. 31, 2016), https://vitalrecord.tamhsc.edu/medication-non-
adherence-people-arent-taking-prescription-medications/(explaining that non-
adherence means patients willfully refusing to do what they should); Id. (“One of 
the aspects of non-adherence is when the patient doesn’t take prescribed drugs 
according to the provider’s instructions. This non-adherence leads to 
hospitalizations when chronic conditions flare up, and these hospitalizations cost 
the health care system between $100 billion and $289 billion each year.”). 
 39 Id. (explaining that even though there are a number of other reasons 
why a person will not get the pharmaceuticals they need price is the largest 
deterrent); see also Pauline W. Chen, When Patients Don’t Fill Their Prescriptions, THE 
NEW YORK TIMES (May 20, 2010), http://www.nytimes.com/2010/05/20/ 
health/20chen.html (explaining patient nonadherence and stating among other 
reasons affordability is an important factor contributing to nonadherence). 
 40 Id. (“Failure to follow prescriptions causes some 125,000 deaths a year 
and up to 10 percent of all hospitalizations.”). 
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brand-name pharmaceuticals or take a high risk of making their 
situations worse. 
IV.  PHARMACEUTICAL PRICING IN CANADA 
Canada has significantly lower pharmaceutical drug prices 
than the United States. In 1987, Canada put the Patented Medicines 
Review Board in place through amendments to the Patent Act in 
response to the North American Free Trade Agreement.41 The 
Canadian federal government set up the Patented Medicine Prices 
Review Board (PMPRB).42 The PMPRB has a dual regulatory and 
reporting mandate.43 The Patented Medicine Prices Review Board 
regulates the price of patented drugs to ensure that the prices are not 
excessive.44 The PMPRB is made up of Board “Staff” and Board 
“Members.”45 The Staff carries out the daily work and is responsible 
for reviewing prices charged for all patented drugs sold in Canada.46 
If a price is found to be excessive, the Staff will try to resolve the 
issue with the patented drug company, but if the price issue is not 
resolved, the Board Members may hold a hearing.47 The Members are 
                                                 
 41 Mandate and Jurisdiction, CANADA PATENTED MEDICAL PRICES REVIEW 
BOARD, http://pmprb-cepmb.gc.ca/about-us/mandate-and-jurisdiction (last 
visited Nov. 13, 2017). 
 42 Id. 
 43 Strategic Plan 2015-2018: The Role of the PMPRB, CANADA PATENTED 
MEDICAL PRICES REVIEW BOARD, http://www.pmprb-cepmb.gc.ca/view.asp 
?ccid=1197#a11 (last visited Nov. 13, 2017), (explaining that the reporting 
mandate requires the PMPRB to report to Parliament annually on its price reviews 
activities, the prices of patented medicines and price trends, and on Research and 
Development expenditures). 
 44 Id. (explaining that the PMPRB “operates independently of Health 
Canada, which approves drugs for safety and efficacy; other health Portfolio 
members, such as the Public Health Agency of Canada, and the Canadian Institute 
for Health Research; and provincial drug plans, which approve the listing of drugs 
on their respective formularies for reimbursement purposes”). 
 45 Id. 
 46 Id. 
 47 Strategic Plan 2015-2018: The Hearing Process, CANADA PATENTED 
MEDICAL PRICES REVIEW BOARD, http://www.pmprb-cepmb.gc.ca/en/hearings 
/the-hearing-process (last visited Nov. 13, 2017) (explaining that at a hearing the 
Board acts as a neutral arbiter between parties before the Board, principally the 
Board Staff and the patentee). 
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appointed by the Governor-in-Council and are responsible for 
conducting hearings when a price is allegedly excessive.48 The Board 
Members have the power to reduce the price of the patented drug or 
order the patented drug company to offset excess revenues, if they 
find that the price is excessive.49 
Canada’s system is different from that of other countries 
because they do not have a national purchasing authority to buy 
patented drugs for the entire population.50 Instead, the PMPRB sets 
price ceilings for all patented drugs.51 The Patented Medicine Prices 
Review Board takes several factors into account when setting these 
ceilings, including the level of therapeutic improvement, domestic 
prices, prices in seven countries, and changes in the Consumer Price 
Index.52 
Nevertheless, Canada’s system of pharmaceutical price 
controls is not without flaws.53 The largest flaw of Canada’s pricing 
system is that it looks at the sticker prices of the same brand-name 
pharmaceuticals in other countries.54 Canada, looking at the sticker 
                                                 
 48 Id. 
 49 Patented Medicine Prices Review Board, GOVERNMENT OF CANADA, 
https://www.canada.ca/en/patented-medicine-prices-review.html (last visited 
Nov. 13, 2017). 
 50 Strategic Plan 2015-2018: The Pharmaceutical Environment in Canada, 
CANADA PATENTED MEDICAL PRICES REVIEW BOARD, http://www.pmprb-
cepmb.gc.ca/view.asp?ccid=1197#a11, (last visited Nov. 13, 2017). 
 51 Id. 
 52 The countries Canada compares their pharmaceutical prices with are 
France, Germany, Italy, Sweden, Switzerland, the United Kingdom, and the United 
States. Id. 
 53 See generally Karen L. Tang, William A. Ghali, & Braden J. Manns, 
Addressing cost-related barriers to prescription drug use in Canada, 186(4) CMAJ: 
CANADIAN MEDICAL ASSOCIATION JOURNAL. 276, 276-280 (2014) (explaining that 
the Patented Medicine Review Board currently compares prices to countries with 
some of the highest drug prices worldwide and they should instead compare to 
countries with lower prices in order to lower brand-name pharmaceutical prices in 
Canada). 
 54 Brendan Murphy, Note: Getting High on Profits: An Analysis of Current State 
and Federal Proposals to Rein in Soaring Drug Prices, 12 J. HEALTH & BIOMED. L. 37, 84 
(2016) (citing Sean Davidson, Drug Price Regulations Need Overhaul to Protect Consumers, 
Experts Say, CBC.CA (Sept. 23, 2015), http://www.cbc.ca/news/health/ 
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prices of brand-name pharmaceuticals in other countries for 
comparison, does not take into account the final price the country 
pays for the pharmaceutical.55 In other words, Canada does not take 
into account the rebates other countries receive from brand-name 
pharmaceutical companies.56 Therefore, the price Canada refers to is 
not the final price that other countries pay for the brand-name 
pharmaceutical. Considering other countries’ pre-rebate prices, leads 
to Canadians paying higher prices than the other countries do for the 
same brand-name pharmaceuticals.57 
V.  PHARMACEUTICAL PRICING IN THE UNITED KINGDOM 
In the United Kingdom, the Pharmaceutical Price Regulation 
Scheme (PPRS) has been in existence since 1957.58 In the United 
Kingdom, the prices of brand-name pharmaceuticals supplied to the 
National Health Service (NHS) are regulated by either a voluntary 
agreement or by the Health Service Branded Medicines Regulations.59 
The voluntary agreement, the Pharmaceutical Price Regulation 
Scheme (PPRS), is between the Department of Health and the 
Association of the British Pharmaceutical Industry (ABPI), which 
deals with the supply of branded drugs to the National Health 
Service.60 The agreement is normally negotiated for a period of five 
                                                 
prescription-drug-prices-1.3239317 (discussing that drug prices for patented drugs 
are calculated using a median average of prices from other countries, comparing 
Canada’s pharmaceutical price regulations to other countries and assessing the 
impact of the disparities between them). 
 55 Id. 
 56 A rebate is a “return of a portion of a purchase price by a seller to a 
buyer, usually on purchase of a specified quantity, or value, of goods within a 
specified period. Unlike discount (which is deducted in advance of payment), rebate 
is given after the payment of full invoice amount.” Rebate, DICTIONARY.COM, 
http://www.dictionary.com/browse/rebate (last visited Nov. 13, 2017). 
 57 See Murphy, supra note 54. 
 58 Understanding the 2014 Pharmaceutical Price Regulation Scheme, THE 
ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY, http://www.abpi. 
org.uk/our-work/policyparliamentary/ Documents/understand ing_pprs2014.pdf 
(last visited Nov. 13, 2017). 
 59 Id. 
 60 Id. 
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years and then renegotiated thereafter.61 The current scheme is the 
2014 Pharmaceutical Price Regulation Scheme, which became 
effective on January 1, 2014.62 The agreement regulates the profit that 
brand-name drug companies can generate, instead of regulating the 
price of the drugs directly, like some other countries do.63 Any brand-
name pharmaceutical company that supplies the NHS with 
pharmaceuticals can participate in this scheme.64 
Simply stated, the Pharmaceutical Price Regulatory Scheme 
regulates the cost of the brand-name pharmaceuticals by limiting the 
amount of profit pharmaceutical companies may generate.65 
Pharmaceuticals are then allocated domestically in the United 
Kingdom through the National Health Service. If pharmaceutical 
companies are not satisfied with the price negotiated by the 
Pharmaceutical Price Regulatory Scheme, they can sell their 
pharmaceuticals privately. Pharmaceutical companies who chose to 
sell their pharmaceuticals privately automatically fall under the 
Statutory Scheme which imposes a list price cut of 15 percent on all 
products.66 Even though membership to the Pharmaceutical Price 
Regulatory Scheme is voluntary, most pharmaceutical companies 
                                                 
 61 Id. (explaining that the PPRS is usually negotiated for a period of five 
years, but has often lasted longer than five years and has only once been terminated 
before the agreement was to expire). 
 62 The 2014 Pharmaceutical Price Regulation Scheme will terminate on 
December 31, 2018. Id. 
 63 Murphy, supra note 54 (“It regulates the profit that companies can 
achieve on sales to the NHS, rather than regulating prices directly. However, it 
does not guarantee profit. Instead, it is based on a range of maximum allowances 
covering R&D, manufacturing costs, information, sales and marketing, and general 
administrative costs. These are then subject to a maximum percentage profit. The 
underlying assessment of profit remains the core basis of the 2014 PPRS.”). 
 64 Pharmaceutical companies who choose not to participate in the PPRS 
are regulated by a different set of statues. Id. at 4. 
 65 Id. 
 66 Aurelie Mahalatchimy, Reimbursement of cell-based regenerative therapy in the 
UK and France, 24(2) MED. LAW REV. 234, 234 (2016) (citing The Health Service 
Medicines (Control of Prices and Supply of Information) (Amendment) 
Regulations 2013, Statutory Instrument No. 2881) (explaining the scheme 
pharmaceutical companies follow when they do not participate in voluntary 
negotiations). 
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choose to join.67 The purpose of the Scheme is to ensure that safe 
and effective pharmaceuticals are available on reasonable terms with 
the NHS and to maintain a strong, efficient, and profitable 
pharmaceutical industry.68 
VI.  ALLOWING MEDICARE TO NEGOTIATE DIRECTLY WITH 
PHARMACEUTICAL COMPANIES 
A.  Explanation of How Negotiation Would Lower Pharmaceutical 
Prices 
Allowing Medicare to negotiate directly with pharmaceutical 
companies is the most effective way to lower the price of 
pharmaceuticals. Medicare would be able to lower pharmaceutical 
prices through negotiation because all developed countries that allow 
negotiation with pharmaceutical companies pay lower prices for 
pharmaceuticals than the United States. As previously stated, 
Medicare is the largest purchaser of prescription drugs in the United 
States.69 This gives Medicare significant bargaining power to negotiate 
price with pharmaceutical companies. Bargaining power in 
negotiations is the ability of one party to dominate the other due to 
its influence, power, size, status, or through a combination of other 
different persuasion tactics.70 
Moreover, pharmaceutical companies would lower their 
prices if Medicare negotiated with them because the pharmaceutical 
companies have an incentive to keep Medicare as a customer. 
Pharmaceutical companies would lower the price of their 
pharmaceuticals because there would be a threat of lost business if 
Medicare did not buy their pharmaceuticals due to the price. If 
Medicare walked away from a deal because the price of the 
pharmaceutical was too high, pharmaceutical companies would not 
                                                 
 67 Id. 
 68 Understanding the 2014 Pharmaceutical Price Regulation Scheme, supra note 58. 
 69 Jeanne Whalen, Why the U.S. Pays More Than Other Countries for Drugs, 
THE WALL STREET JOURNAL (DEC. 1, 2015, 9:27 PM), https://www.wsj 
.com/articles/why-the-u-s-pays-more-than-other-countries-for-drugs-1448939481. 
 70 Bargaining Power, BUSINESS DICTIONARY, http://www.businessdictionary 
.com/definition/bargaining-power.html (last visited Nov. 13, 2017). 
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make any profit. Additionally, pharmaceutical companies would have 
to find more buyers for their product in an attempt to make up for 
the lost business of the largest purchaser in the industry. This would 
prove to be time consuming and use more of the companies’ 
resources. Therefore, it follows that pharmaceutical companies would 
likely lower the price of pharmaceuticals because a decrease in profit 
is better than making no profit at all. These pharmaceutical 
companies could lower their prices to a point where they could still 
make a profit while making the price attractive to Medicare. The 
additional business the pharmaceutical companies would receive 
from Medicare in the future, would justify the reduction in price. 
In addition, pharmaceutical companies can still retain their 
bargaining power. The Centers for Medicare and Medicaid Services 
(CMS) force prescription drug plans (PDPs) to cover almost all drugs 
in certain categories.71 This requirement has a number of effects on 
the negotiation process.72 This gives pharmaceutical companies 
bargaining power because Medicare would not be able to walk away 
from a deal if they are required to cover the drug. Additionally, this 
requirement protects consumers. Consumers would not have to fear 
that a brand-name pharmaceutical they need will not be covered 
because of Medicare’s ability to negotiate with pharmaceutical 
companies. If Medicare is required to cover a drug, it has no choice 
but to purchase the drug. 
However, this will only be the case if only one or two drugs 
are offered on the market. If there are multiple drugs on the market, 
Medicare can choose to obtain a lower price on a substitute from a 
pharmaceutical competitor. This will encourage competition among 
pharmaceutical companies competing for Medicare’s business. This 
competition between pharmaceutical companies would cause the 
                                                 
 71 Report to Congress: Medicare Payment Policy, MEDICARE PAYMENT 
ADVISORY COMMISSION at 401, (March 23, 2016), http://medpac.gov/docs/ 
default-source/reports/mar17_entirereport.pdf (explaining “[f]or six drug classes, 
CMS requires Part D plans to cover “all or substantially all” drugs in the class 
(protected class)”). 
 72 Id. (“This policy is intended to allow competition in classes with multiple 
products while protecting beneficiaries who need a drug that is the only one 
available to treat a certain condition.”). 
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pharmaceutical companies to lower their prices so Medicare will buy 
their product and not their competitor’s product. 
B.  Canada and the United Kingdom as a Model for Pharmaceutical 
Pricing 
The United States should implement a pharmaceutical pricing 
system, that models parts of the systems currently in place in Canada 
and in the United Kingdom, to negotiate and set brand-name 
pharmaceutical prices. The United States should allow brand-name 
pharmaceutical companies to choose whether or not they want to 
negotiate with Medicare, just as the United Kingdom allows 
pharmaceutical companies to choose whether or not they want to 
participate in the Pharmaceutical Price Regulation Scheme (PPRS).73 
Further, if certain brand-name pharmaceutical companies choose not 
to negotiate with Medicare, they would be subject to pricing 
regulations. This mirrors the United Kingdom’s system wherein 
pharmaceutical companies that do not participate in the 
Pharmaceutical Price Regulation Scheme are subject to separate 
regulations.74 
The United Kingdom regulates the amount of profit brand-
name pharmaceutical companies can generate rather than setting a 
cap on the price of the pharmaceutical.75 The United States should 
implement a regulation regime similar to the United Kingdom’s. This 
method ensures that brand-name pharmaceutical companies are 
generating a profit and not just covering their costs.76 It is important 
that brand-name pharmaceutical companies continue to realize a 
profit or they would stop manufacturing the pharmaceuticals to avoid 
                                                 
 73 See Murphy, supra note 54. (prices of brand-name pharmaceuticals 
supplied to the National Health Service (NHS) are regulated by either a voluntary 
agreement, or the Health Service Branded Medicines Regulations). 
 74 Understanding the 2014 Pharmaceutical Price Regulation Scheme, supra note 58. 
 75 Id. 
 76 Id. (explaining that the United Kingdom’s Pharmaceutical Price 
Regulation Scheme allows companies to make a reasonable profit to enable them to 
continue investing in the development of new pharmaceuticals and setting a limit 
on profit helps secure value for money for the NHS). 
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losses.77 Moreover, regulating the profit rather than the final price of 
a pharmaceutical would aid in safeguarding the profitability of the 
pharmaceutical companies. 
Regulating the profit a pharmaceutical company could 
generate, would reduce the price of pharmaceuticals. For example, if 
a brand-name pharmaceutical company was only permitted to 
generate $1 of profit on each pharmaceutical sold and the cost of 
production was $1, the price of the pharmaceutical could not exceed 
$2. The United Kingdom’s Scheme recognizes the importance of 
balancing the interests of the pharmaceutical industry and the 
interests of patients.78 The United States should regulate profit like 
the United Kingdom does because it strikes the needed balance 
between the interests of brand-name pharmaceutical companies, that 
are in business to make profit, and the interests of the citizens, who 
need the pharmaceuticals to remain in good health. 
The United States should also put a board in place to be 
responsible for setting a cap, or limit, on the amount of profit brand-
name pharmaceutical companies could generate if they chose not to 
negotiate with Medicare. The Canadian federal government set up the 
Patented Medicine Prices Review Board, which is responsible for 
overseeing the prices of brand-name pharmaceuticals and ensuring 
that the prices are not excessive.79 The United States should create a 
board similar to Canada’s Board. This board could consider a range 
of factors when setting the cap on the amount of profit brand-name 
pharmaceutical companies could generate from their pharmaceuticals. 
The United States board could consider factors that are similar to the 
factors Canada’s Patented Medicine Prices Review Board considers 
                                                 
 77 Although discovering new drugs is important to pharmaceutical 
companies there must be a potential to make profit. “People invest in areas where 
they can get a return on their investment. An area . . . which offers no possible 
return on investment would be summarily dismissed.” John LaMattina, ‘Do Drug 
Companies Make Drugs, Or Money?’, FORBES (July 29, 2014, 9:03AM), 
http://www.forbes.com/sites/johnlamattina/2014/07/29/do-drug-companies-
make-drugs-or-money/#237b8db47fcf. 
 78 Understanding the 2014 Pharmaceutical Price Regulation Scheme, supra note 58 
(stating “The PPRS recognizes the importance of striking a balance to promote the 
common interests of patients, the NHS, the industry and the taxpayer”). 
 79 Strategic Plan 2015-2018: The Role of the PMPRB, supra note 43. 
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when determining the price ceiling for pharmaceuticals. The Patented 
Medicine Prices Review Board takes several factors into account 
when setting the price ceiling, including the level of therapeutic 
improvement, domestic prices, prices in seven other countries, and 
changes in the Consumer Price Index.80 
As a cautionary note, the United States should learn from the 
flaws in Canada’s system and consider the price of pharmaceuticals in 
other countries after rebates. The United States should not merely 
look at the sticker price of the pharmaceuticals in other countries as 
Canada does because that sticker price decreases after rebates. 
C.  Arguments Against Medicare Negotiating with Brand-name 
Pharmaceutical Companies 
It is argued that Medicare should not be allowed to directly 
negotiate with pharmaceutical companies. One of the main 
arguments is that it will adversely impact research and development 
(R&D).81 It is argued that if Medicare was allowed to negotiate with 
pharmaceutical companies, the price of the company’s product would 
fall and as a result they would have less money to advance research 
and development. As a consequence of less research and 
development, fewer drugs would be brought to market. 
Pharmaceutical Research and Manufacturers of America (PhRMA) 
argues that high pharmaceutical prices are due to the cost of research 
and development to bring a new drug to market.82 Many drugs do not 
even make it to the market.83 PhRMA claims that it takes 
                                                 
 80 Strategic Plan 2015-2018: The Pharmaceutical Environment in Canada, supra 
note 50. 
 81 See Joseph Gulfo, Medicare negotiating with pharma is not the answer, THE 
HILL (Dec. 4, 2015, 7:00 AM), http://thehill.com/blogs/pundits-
blog/healthcare/262077-medicare-negotiating-with-pharma-is-not-the-answer. 
 82 See Kounang, supra note 1. 
 83 California Biomedical Research Association, Fact Sheet: New Drug 
Development Process, CALIFORNIA BIOMEDICAL RESEARCH ASSOCIATION, http:// 
www.ca-biomed.org/pdf/media-kit/fact-sheets/FS-DrugDevelop.pdf (last visited 
Nov. 13, 2017) (explaining that it takes approximately 12 years for a drug to make it 
to the patient, and only 1 in 5,000 drugs are approved for patient usage); see also 
Drug Approvals- From Invention to Market . . . A 12- Year Trip, MEDICALNET.COM, 
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approximately ten years and around two and a half billion dollars to 
bring a new drug to the market.84 
However, lower pharmaceutical prices will not necessarily 
decrease research and development in pharmaceuticals. Past research 
and development costs are not very relevant to the present price of 
the pharmaceutical because the price is determined by the demand 
for the pharmaceutical.85 Further, the prices charged for 
pharmaceuticals are the prices the market will bear.86 Although some 
costs of research and development are passed to the buyer, 
pharmaceutical companies also share the expense and consider it a 
sunk cost.87 Healthcare America Now explained that research and 
development would not suffer as a result of lower pharmaceutical 
prices because, from 1998 to 2007, half of the innovative drugs 
approved resulted from research done by universities and biotech 
firms, not pharmaceutical companies.88 
In addition, pharmaceutical companies spend nineteen times 
more on marketing their products than on research and 
                                                 
http://www.medicinenet.com/script/main/art.asp?articlekey=9877 (last visited 
Nov. 13, 2017). 
 84 See Kounang, supra note 1. 
 85 Tomas Philipson, Why the Drug Industry and Its Critics Are Both Wrong 
About How R&D Spending Affects Pricing, FORBES (Oct. 6, 2016), 
http://www.forbes.com/sites/tomasphilipson/2016/10/06/why-the-drug-
industry-and-its-critics-are-both-wrong-about-how-rd-spending-affects-
pricing/#cb5980df9818 (explaining that past research and development costs 
should not be given great weigh when setting the price of a brand-name 
pharmaceutical, instead the prices of the brand-name pharmaceuticals drive 
Research and Development spending). 
 86 Id. 
 87 See Sunk cost, BUSINESS DICTIONARY, http://www.business dictionary 
.com/definition/sunk-cost.html (last visited Nov. 13, 2017) (“Money already spent 
and permanently lost. Sunk costs are pat opportunity costs that are partially (as 
salvage, if any) or totally irretrievable and, therefore, should be considered 
irrelevant to future decision making . . . Also called embedded cost, prior year cost, 
standard cost, or sunk capital.”). 
 88 Legislative Brief Why Can’t Medicare Negotiate Drug Prices with Pharmaceutical 
Companies?, OHIO COUNCIL OF CHURCHES (October 18, 2016), http://diosohio 
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development.89 This high marketing cost shows that pharmaceutical 
companies have the ability to maintain the same level of research and 
development and cut costs in other areas. Additionally, the profit 
generated by pharmaceutical companies is not likely to fall when the 
pharmaceuticals do not have a substitute. Furthermore, if there are 
no other competitors on the market, Medicare would be forced to 
purchase the new pharmaceutical and the pharmaceutical companies 
would generate a large return on their research and development. 
This creates an incentive for pharmaceutical companies to invest in 
research and development and be the first company to bring a 
pharmaceutical to the market. As the first to bring a pharmaceutical 
to the market, profits will be high as a result of market dominance. 
Others argue that Medicare negotiating directly with brand-
name pharmaceutical companies would be impractical.90 The 
argument is that it would not be practical for the Centers for 
Medicare and Medicaid Services to negotiate the prices of 
pharmaceuticals because the process would be extremely time 
consuming and expensive.91 However, this argument is not persuasive 
because the benefit of lower prices of pharmaceuticals greatly 
outweighs the time and expense of the negotiations. Further, the 
Food and Drug Administration (FDA) must examine all 
pharmaceuticals before they reach the market.92 Even though it takes 
the FDA some time to examine all of the pharmaceuticals, it is seen 
as worthwhile. The same logic follows for allowing Medicare to 
negotiate with pharmaceutical companies. Although it could be a 
lengthy process, it would be worthwhile. 
Finally, critics argue that allowing Medicare to negotiate 
directly with pharmaceutical companies will simply not lower the 
                                                 
 89 Id. (explaining that although pharmaceutical companies strongly argue 
attempts to lower prices would kill their research and development, pharmaceutical 
companies spend a lot more money in other areas such as marketing). 
 90 David Nather, Washington has big hopes, but little power, to negotiate drug prices, 
STAT NEWS (Jan. 6, 2016), https://www.statnews.com/2016/01/06/medicare-
negotiate-drug-prices. 
 91 Id. 
 92 Development & Approval Process (Drugs), U.S. FOOD AND DRUG 
ADMINISTRATION, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ 
(last visited Nov. 13, 2017). 
2018 Penn State Journal of Law & International Affairs 6:1 
336 
price of pharmaceuticals.93 It is argued that Medicare will not be able 
to reduce the price of pharmaceuticals because they do not have the 
ability to reject a pharmaceutical.94 They argue that because Congress 
put rules in place to strengthen pharmaceutical companies’ 
negotiations, the need for Medicare to negotiate is unnecessary to 
lower prices.95 Essentially the price of pharmaceuticals will not 
decrease, even if Medicare was allowed to negotiate with 
pharmaceutical companies, because Medicare does not have the 
ability to refuse to buy the drug. 
However, this argument only applies in situations when there 
are only one or two drugs on the market. When there are multiple 
competitors in the market, Medicare would have the leverage 
stemming from the option to buy a competitor’s pharmaceutical. The 
threat of Medicare saying no and buying a competitor’s product 
would motivate a company to lower the price of their pharmaceutical 
so they do not lose a major buyer. 
Additionally, this argument does not favor prohibiting 
Medicare from negotiating directly with pharmaceutical companies. 
This argument merely identifies a step that is required in order for 
Medicare to effectively negotiate with pharmaceutical companies. 
Medicare must be allowed to say no to a pharmaceutical company 
otherwise the use of their bargaining power would be to no avail. The 
threat of not buying a pharmaceutical must be real in order to 
negotiate lower prices. 
The United States currently has a government program in 
place that is allowed to negotiate with pharmaceutical companies and 
refuse to buy the pharmaceutical, the Department of Veterans 
                                                 
 93 Margot Sanger-Katz, The Real Reason Medicare Is a Lousy Drug Negotiator: It 
Can’t Say No, THE NEW YORK TIMES (Feb. 2, 2016), http://www.nytimes 
.com/2016/02/02/upshot/the-real-reason-medicare-is-a-lousy-drug-negotiator-it-
cant-say-no.html?_r=0. 
 94 Id. 
 95 Id. (explaining that Medicare must cover most pharmaceuticals and 
would need to be bound by fewer rules and have the ability to say no to 
pharmaceutical companies which would result in less drugs being covered by 
Medicare). 
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Affairs.96 The Veterans Administration offers a drug benefit with 
lower costs than Medicare beneficiaries receive. The Veteran’s 
Administration imposes price ceilings on some drugs and also 
negotiates with pharmaceutical companies for discounts.97 This 
demonstrates that it is possible to allow Medicare to refuse to buy a 
drug from pharmaceutical companies. Therefore, the argument is 
unfounded. 
VII.  OTHER SUGGESTED REFORMS TO LOWER THE COST OF 
PHARMACEUTICALS 
There are multiple other reform proposals suggested to lower 
the prices of pharmaceuticals in the United States, including 
increasing the number of generic pharmaceuticals and importing 
pharmaceuticals from foreign countries.98 However, these proposals 
would not be as effective in lowering pharmaceutical prices as 
allowing Medicare to negotiate directly with pharmaceutical 
companies. 
It is argued that increasing the number of generic 
pharmaceuticals on the market will cause pharmaceutical prices to 
drop. A generic drug is a drug that is comparable to a brand-name 
drug in dosage, strength, administration, quality, and performance.99 
In the United States nearly 8 to 10 prescriptions filled are for generic 
drugs.100 Additionally, research shows that generics work as well as 
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 97 John E. Dicken, Prescription Drugs: An Overview of Approaches to Negotiate 
Drug Prices Used by Other Countries and U.S. Private Payors and Federal Programs, 
Testimony before the United States Senate, GAO-07-358T (Jan. 11, 2007). 
 98 See generally Paula Tironi, Article: Pharmaceutical Pricing: A Review of Proposals 
to Improve Access and Affordability of Prescription Drugs, 19 ANN. HEALTH L. 311 (2010). 
 99 Abbreviated New Drug Application (ANDA), U.S. FOOD AND DRUG 
ADMINISTRATION, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ 
HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDr
ugApplicationANDAGenerics/default.htm (last visited Nov. 13, 2017). 
 100 Generic Drugs Facts, U.S. FOOD AND DRUG ADMINISTRATION, 
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brand-name pharmaceuticals.101 However, innovators of new 
pharmaceuticals obtain patents to protect their product from being 
duplicated.102 The owner of a patent can exclude anyone from 
making, using, offering for sale, or selling their invention for twenty 
years from the filing of the patent application.103 This means that 
generic pharmaceuticals cannot be released into the market until the 
innovator’s patent expires. Therefore, increasing the number of 
generic pharmaceuticals cannot happen until the patent expires, 
which defeats this proposal. 
Additionally, when the patents of brand-name pharmaceutical 
companies’ expire, they often pay generic pharmaceutical 
manufacturers to wait to release their generic version.104 This is 
referred to as “pay for delay.”105 These pay for delay deals are made 
so brand-name pharmaceutical companies can continue to generate 
profits with no competition on the market.106 These transactions are 
attractive to generic pharmaceutical companies because the money 
they receive from the brand-name pharmaceutical companies replaces 
the profit they would have made from the sales of their product. The 
FDA also needs to approve the generic pharmaceutical before it goes 
to market, which is a very lengthy process.107 The slow pace of the 
                                                 
 101 Id. (“A study evaluated the results of 38 clinical trials that compared 
cardiovascular generic drugs to their brand-name counterparts. There was no 
evidence that brand-name heart drugs worked any better than generic heart 
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FDA approval process for generic pharmaceuticals reduces the 
competition in the market and therefore, prices of brand-name 
pharmaceuticals are not reduced. For these reasons, increasing the 
number of generic pharmaceuticals on the market will not be an 
effective way to reduce the price of pharmaceuticals. 
Other reform proposals suggest allowing consumers to 
import drugs from other countries.108 Given that the United States 
pays more for prescription drugs than any other developed country, 
this proposal seems attractive. However, the United States Federal 
Food, Drug, and Cosmetic Act prohibits the interstate shipment, 
including importation, of unapproved new drugs.109 In other words, 
the importation of drugs that are not approved by the Food and 
Drug Administration (FDA) violates the Food, Drug, and Cosmetic 
Act except under certain circumstances.110 Unapproved drugs are 
drugs, including foreign-made versions, that have not been 
manufactured in accordance to FDA approval.111 However, as 
previously mentioned in the EpiPen example, people in the United 
                                                 
5-column.html (“The FDA’s years-long backlog of approvals now runs to 
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States often buy pharmaceuticals from foreign countries.112 A major 
concern with drug importation is safety.113 People may think they are 
buying an approved drug, when in reality they are buying a 
counterfeit.114 Some additional safety concerns include incorrect 
doses, contaminated pharmaceuticals, toxic ingredients, and 
ineffectiveness. Further, federal regulators cannot guarantee where or 
how drugs sold abroad were made.115 The FDA also has a limited 
ability to take action against these foreign sellers.116 People buying 
foreign pharmaceuticals must rely on the foreign governments to 
inspect the pharmaceuticals. These foreign governments may not 
inspect the pharmaceuticals as thoroughly as the United States 
government. Legalizing the importation of pharmaceuticals from 
foreign countries would create more problems than benefits. 
VIII.  CONCLUSION 
In conclusion, Medicare should be allowed to negotiate 
directly with brand-name pharmaceutical companies in order to 
reduce the price of pharmaceuticals. Medicare should be allowed to 
use their bargaining power to reduce the price of brand-name 
pharmaceuticals. This comment described how Canada and the 
United Kingdom have achieved lower prices for brand-name 
pharmaceuticals and suggests that the United States should adopt 
certain aspects of both Canada’s system and the United Kingdom’s 
system to create an efficient, effective, and safe system for its citizens. 
Pharmaceutical pricing is an extremely important issue that will affect 
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most people throughout their lifetime. No person should be 
restricted from receiving proper treatment because they cannot 
afford to buy the pharmaceuticals they need. Allowing Medicare to 
negotiate directly with brand-name pharmaceutical companies is the 
most effective way to cure the high costs of pharmaceuticals in 
America. 
